AUSTIN, Texas, Nov. 24, 2020 /PRNewswire/ -- Aeglea
BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology
company developing a new generation of human enzyme therapeutics as
innovative solutions for rare and other high-burden diseases, today
announced updated timing for its Fireside Chat presentation at an
upcoming investor conference hosted by Evercore.
Updated Conference Details
Conference Name: Evercore ISI 3rd Annual HealthCONx
Conference
Conference Date: December 1-3, 2020
Fireside Chat Date/Time: December 1,
2020 at 8:00 a.m. EST
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea's
president and chief executive officer
To access the live and archived webcast, visit the Presentations
& Events section of the Company's website. Please connect to
the website at least 15 minutes prior to the presentation to allow
for any software download that may be necessary. An archived
version of the webcasts will also be available through the
Company's website for a limited time following the conference.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company
redefining the potential of human enzyme therapeutics to benefit
people with rare and other high burden diseases. Aeglea's lead
product candidate, pegzilarginase, is in a pivotal Phase 3 trial
for the treatment of Arginase 1 Deficiency and has received both
Rare Pediatric Disease and Breakthrough Therapy Designation. The
Company initiated a Phase 1/2 clinical trial of ACN00177 for the
treatment of Homocystinuria in the second quarter of 2020. Aeglea
has an active discovery platform, with the most advanced program
for Cystinuria. For more information, please visit
http://aegleabio.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference-301180126.html
SOURCE Aeglea BioTherapeutics, Inc.